Driscoll D F, Bacon M N, Bistrian B R
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
JPEN J Parenter Enteral Nutr. 2000 Jan-Feb;24(1):15-22. doi: 10.1177/014860710002400115.
Recent data have demonstrated that total nutrient admixtures (TNAs) are unstable when the percentage of fat (PFAT) globules >5 microm in diameter constitute >0.4% of the total fat present and therefore can be considered pharmaceutically unfit for human administration.
We studied five nutritionally balanced TNAs using two different products of different oil composition designed to feed adult patients weighing 40 to 80 kg in 10 kg increments, which were given in final volumes equal to 25 mL/kg. Final concentrations of amino acids, dextrose, and lipids were held constant for each weight level. To provide cationic stress within clinical limits, calcium and magnesium were given in amounts equal to three times the usual daily dose, at 15 mmol each. Five TNAs were made in duplicate and for each product (n = 20) and studied over 5 days. Lipid droplet counts were determined by laser light extinction and conducted at five intervals; immediately after preparation at time 1 (T1), after 4 days at 4 degrees C +/- 2 degrees C (T2), and then at 6 (T3), 24 (T4), and 30 (T5) hours during storage at 25 degrees C +/- 1 degree C. At T3, a simulated patient infusion, set at a rate to deliver the entire volume over the next 24 hours, was begun. Samples taken at T3, T4, and T5, equal to 0, 18, and 24 hours, respectively, of the simulated patient infusion, were collected from the terminal infusion port of the i.v. administration set. Mean particle size (MPS) was determined by dynamic light scatter at T1, T3, and T5. Dependent variable analyses included the PFAT globules > 1.75 and 5 microm and MPS. A repeated-measure two-way ANOVA assessing treatment and time was performed.
The MCT/LCT-based TNAs had significantly fewer enlarged fat globules >1.75 microm (p < .0001) and >5 microm (p = .046), and smaller MPS (p < .0001) than TNAs made with the pure LCT emulsion. Of the 20 TNAs studied, 4 demonstrated visible evidence of instability (ie, heavy creaming or free oil), each occurring on day 5 only with the 70- and 80-kg LCT-based TNAs, and no evidence of instability with admixtures prepared from MCT/LCT lipid emulsions (chi2 analysis: p < .05).
Because the final macronutrient concentrations were held constant, the instability seen with the LCT-based TNAs of higher volumes may result from dilution of the electrolyte concentrations that unfavorably alters the electrical double layer and irreversibly commits the emulsion to an unstable state. The greater physicochemical stability achieved with the MCT/LCT-based TNAs, in turn, likely results from the smaller lipid droplet sizes, which may be an inherent property of MCTs.
最近的数据表明,当直径>5微米的脂肪(PFAT)球粒占总脂肪的比例>0.4%时,全营养混合液(TNA)是不稳定的,因此在药学上可被认为不适用于人体给药。
我们使用两种不同油成分的产品研究了五种营养均衡的TNA,设计用于喂养体重40至80千克的成年患者,以10千克为增量,最终体积为25毫升/千克。每种体重水平下氨基酸、葡萄糖和脂质的最终浓度保持恒定。为了在临床限度内提供阳离子应激,钙和镁的给药量为通常每日剂量的三倍,各为15毫摩尔。每种产品(n = 20)的五种TNA均重复制备两份,并研究5天。通过激光消光法测定脂质滴计数,并在五个时间点进行;在制备后立即于时间1(T1)、在4℃±2℃下保存4天后(T2),然后在25℃±1℃下保存期间的6(T3)、24(T4)和30(T5)小时进行。在T3时,开始模拟患者输注,设定速率以便在接下来的24小时内输注完整个体积。在T3、T4和T5时采集的样本,分别相当于模拟患者输注的0、18和24小时,从静脉给药装置的末端输注端口采集。在T1、T3和T5时通过动态光散射法测定平均粒径(MPS)。相关变量分析包括直径>1.75和5微米的PFAT球粒以及MPS。进行了评估治疗和时间的重复测量双向方差分析。
与用纯LCT乳剂制成的TNA相比,基于MCT/LCT的TNA中直径>1.75微米(p <.0001)和>5微米(p =.046)的增大脂肪球明显更少,且MPS更小(p <.0001)。在所研究的20种TNA中,有4种显示出不稳定的明显迹象(即严重分层或游离油),每种情况仅在第5天出现在基于LCT的70千克和80千克TNA中,而用MCT/LCT脂质乳剂制备的混合液没有不稳定的迹象(卡方分析:p <.05)。
由于最终的常量营养素浓度保持恒定,较高体积的基于LCT的TNA中出现的不稳定可能是由于电解质浓度的稀释,这不利地改变了双电层并使乳剂不可逆地进入不稳定状态。基于MCT/LCT的TNA所实现的更高物理化学稳定性,反过来可能是由于脂质滴尺寸更小,这可能是MCT的固有特性。